Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DETECT III - A Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients With Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells

NCT01619111 is registered in ClinicalTrials.gov with Prof. Wolfgang Janni as lead sponsor.

NCT NCT01619111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01619111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DETECT III - A Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients With Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells
Lead sponsor
Prof. Wolfgang Janni
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2012
Completion date
January 31, 2022
Enrollment
105 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative metastatic breast cancer, her2-positive circulating tumor cells